PL2222648T3 - Pochodne pirymidyny do leczenia astmy, POChP, alergicznego nieżytu nosa, alergicznego zapalenia spojówki, atopowego zapalenia skóry, nowotworu, zapalenia wątroby typu B, zapalenia wątroby typu C, HIV, HPV, zakażeń bakteryjnych i dermatozy - Google Patents

Pochodne pirymidyny do leczenia astmy, POChP, alergicznego nieżytu nosa, alergicznego zapalenia spojówki, atopowego zapalenia skóry, nowotworu, zapalenia wątroby typu B, zapalenia wątroby typu C, HIV, HPV, zakażeń bakteryjnych i dermatozy

Info

Publication number
PL2222648T3
PL2222648T3 PL08851708T PL08851708T PL2222648T3 PL 2222648 T3 PL2222648 T3 PL 2222648T3 PL 08851708 T PL08851708 T PL 08851708T PL 08851708 T PL08851708 T PL 08851708T PL 2222648 T3 PL2222648 T3 PL 2222648T3
Authority
PL
Poland
Prior art keywords
hepatitis
dermatosis
hpv
copd
hiv
Prior art date
Application number
PL08851708T
Other languages
English (en)
Polish (pl)
Inventor
Nicholas J Bennett
Thomas Mcinally
Tobias Mochel
Stephen Thom
Anna-Karin Tidén
Original Assignee
Astrazeneca Ab
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Dainippon Sumitomo Pharma Co filed Critical Astrazeneca Ab
Publication of PL2222648T3 publication Critical patent/PL2222648T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL08851708T 2007-11-22 2008-11-21 Pochodne pirymidyny do leczenia astmy, POChP, alergicznego nieżytu nosa, alergicznego zapalenia spojówki, atopowego zapalenia skóry, nowotworu, zapalenia wątroby typu B, zapalenia wątroby typu C, HIV, HPV, zakażeń bakteryjnych i dermatozy PL2222648T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0702577 2007-11-22
US1369907P 2007-12-14 2007-12-14
EP08851708A EP2222648B1 (en) 2007-11-22 2008-11-21 Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis
PCT/SE2008/051334 WO2009067081A1 (en) 2007-11-22 2008-11-21 Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis

Publications (1)

Publication Number Publication Date
PL2222648T3 true PL2222648T3 (pl) 2013-05-31

Family

ID=40667750

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08851708T PL2222648T3 (pl) 2007-11-22 2008-11-21 Pochodne pirymidyny do leczenia astmy, POChP, alergicznego nieżytu nosa, alergicznego zapalenia spojówki, atopowego zapalenia skóry, nowotworu, zapalenia wątroby typu B, zapalenia wątroby typu C, HIV, HPV, zakażeń bakteryjnych i dermatozy

Country Status (35)

Country Link
US (2) US8268990B2 (enExample)
EP (1) EP2222648B1 (enExample)
JP (1) JP5638394B2 (enExample)
KR (1) KR101663326B1 (enExample)
CN (2) CN103342682A (enExample)
AR (1) AR069412A1 (enExample)
AU (1) AU2008326863B2 (enExample)
BR (1) BRPI0819788A2 (enExample)
CA (1) CA2704214C (enExample)
CL (1) CL2008003480A1 (enExample)
CO (1) CO6270324A2 (enExample)
CR (1) CR11451A (enExample)
CY (1) CY1113846T1 (enExample)
DK (1) DK2222648T3 (enExample)
DO (1) DOP2010000153A (enExample)
EA (1) EA018121B1 (enExample)
EC (1) ECSP10010294A (enExample)
ES (1) ES2401401T3 (enExample)
HN (1) HN2010001059A (enExample)
HR (1) HRP20130174T1 (enExample)
IL (1) IL205513A0 (enExample)
ME (1) ME01515B (enExample)
MX (1) MX2010005435A (enExample)
NZ (1) NZ585313A (enExample)
PE (1) PE20091236A1 (enExample)
PL (1) PL2222648T3 (enExample)
PT (1) PT2222648E (enExample)
RS (1) RS52694B (enExample)
SA (1) SA08290741B1 (enExample)
SI (1) SI2222648T1 (enExample)
TW (1) TWI461198B (enExample)
UA (1) UA99484C2 (enExample)
UY (1) UY31481A1 (enExample)
WO (1) WO2009067081A1 (enExample)
ZA (1) ZA201003476B (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI392678B (zh) 2004-03-26 2013-04-11 Dainippon Sumitomo Pharma Co ９-取代-８-氧基腺嘌呤化合物
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
WO2008004948A1 (en) * 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
WO2008114008A1 (en) * 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
EP2139894B1 (en) * 2007-03-19 2011-10-26 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
EP2138497A4 (en) * 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
AR065784A1 (es) * 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
JP5400763B2 (ja) * 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
ES2541434T3 (es) * 2007-06-29 2015-07-20 Gilead Sciences, Inc. Derivados de purina y su uso como moduladores del receptor de tipo Toll 7
US8440681B2 (en) 2007-08-28 2013-05-14 Irm Llc 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
EA026557B1 (ru) 2008-12-09 2017-04-28 Джилид Сайэнс, Инк. Промежуточные соединения для получения модуляторов толл-подобных рецепторов
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
CA2760766A1 (en) * 2009-05-21 2010-11-25 Nicholas James Bennett Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
US9567318B2 (en) 2009-08-17 2017-02-14 Memorial Sloan-Kettering Cancer Center Substituted pyrimidine compounds and uses thereof
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
US8507507B2 (en) 2009-10-22 2013-08-13 Gilead Sciences, Inc. Modulators of toll-like receptors
EP2507237A1 (en) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
JP2013147428A (ja) * 2010-04-27 2013-08-01 Dainippon Sumitomo Pharma Co Ltd 新規２−ヘテロアリール単環ピリミジン誘導体
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
WO2012066336A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
EP2640716A1 (en) * 2010-11-19 2013-09-25 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amide compounds and their use in the treatment of disease
WO2012067269A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012066335A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
US8895570B2 (en) 2010-12-17 2014-11-25 Astrazeneca Ab Purine derivatives
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
CA2814014A1 (en) 2011-01-21 2012-07-26 Branko MITASEV Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
ES2681698T3 (es) 2011-03-02 2018-09-14 Glaxosmithkline Biologicals Sa Vacunas de combinación con menores dosis de antígeno y/o adyuvante
EA027792B1 (ru) 2011-04-08 2017-09-29 Янссен Сайенсиз Айрлэнд Юси Производные пиримидина для лечения вирусных инфекций
HRP20180447T1 (hr) * 2011-05-18 2018-04-20 Janssen Sciences Ireland Uc Derivati kinazolina za liječenje virusnih infekcija i drugih bolesti
US20140363461A1 (en) 2011-09-01 2014-12-11 Fabio Bagnoli Adjuvanted formulations of staphylococcus aureus antigens
CN104066733A (zh) 2011-11-09 2014-09-24 爱尔兰詹森研发公司 用于治疗病毒感染的嘌呤衍生物
EA033907B1 (ru) 2012-02-08 2019-12-09 Янссен Сайенсиз Айрленд Юси Производные пиперидино-пиримидина, фармацевтическая композиция и их применение
CN104582726A (zh) 2012-03-07 2015-04-29 诺华股份有限公司 狂犬病病毒免疫原的含佐剂制剂
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
KR102091895B1 (ko) * 2012-05-03 2020-04-14 제넨테크, 인크. 파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체
JP6184423B2 (ja) 2012-05-18 2017-08-23 大日本住友製薬株式会社 カルボン酸化合物
SG11201408542VA (en) 2012-07-13 2015-02-27 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
EP2882721B1 (en) * 2012-08-10 2018-12-05 Janssen Sciences Ireland Unlimited Company Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
EP2712866A1 (en) * 2012-10-01 2014-04-02 Centre National de la Recherche Scientifique (CNRS) 1,2,4-triazine derivatives for the treatment of viral infections
KR102252649B1 (ko) 2012-10-05 2021-05-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 추가 질환의 치료를 위한 아실아미노피리미딘 유도체
KR102280595B1 (ko) * 2012-10-10 2021-07-22 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 다른 질환 치료를 위한 피롤로[3,2-d]피리미딘 유도체
WO2014057132A1 (en) 2012-10-12 2014-04-17 Novartis Ag Non-cross-linked acellular pertussis antigens for use in combination vaccines
CN105051018B (zh) 2012-11-16 2019-09-20 爱尔兰詹森科学公司 用于治疗病毒性感染的杂环的经取代的2-氨基-喹唑啉衍生物
WO2014118305A1 (en) 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
CN105189468B (zh) 2013-02-21 2018-10-30 爱尔兰詹森科学公司 用于治疗病毒性感染的2-氨基嘧啶衍生物
MX366481B (es) * 2013-03-29 2019-07-09 Janssen Sciences Ireland Uc Deaza-purinonas macrociclicas para el tratamiento de infecciones virales.
SG11201509265SA (en) 2013-05-10 2015-12-30 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
DK3004074T3 (da) * 2013-05-24 2018-01-29 Janssen Sciences Ireland Uc Pyridonderivater til behandling af virusinfektioner og yderligere sygdomme
NO3030563T3 (enExample) * 2013-06-27 2018-01-06
MX368625B (es) 2013-07-30 2019-10-08 Janssen Sciences Ireland Uc Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales.
HUE047808T2 (hu) 2014-03-26 2020-05-28 Glaxosmithkline Biologicals Sa Mutáns Staphylococcus antigének
AU2015259173B2 (en) 2014-05-13 2019-09-05 Memorial Sloan Kettering Cancer Center Hsp70 modulators and methods for making and using the same
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
AU2015318061B2 (en) 2014-09-16 2018-05-17 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
CN105111151B (zh) * 2015-04-17 2018-09-28 成都理工大学 作为PPAR-γ调节剂的氨基嘧啶衍生物
AU2016271857B2 (en) 2015-06-03 2020-05-28 Affiris Ag IL-23-P19 vaccines
CA2991544A1 (en) 2015-07-07 2017-01-12 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
CN108290845B (zh) 2015-10-07 2021-08-03 大日本住友制药株式会社 嘧啶化合物
CA3027471A1 (en) 2016-07-01 2018-01-04 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
CN109790154B (zh) 2016-09-29 2023-06-23 爱尔兰詹森科学公司 用于治疗病毒感染和另外的疾病的嘧啶前药
CA3045517A1 (en) * 2016-12-05 2018-06-14 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
US10786502B2 (en) * 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
FI3603619T3 (fi) 2017-03-29 2025-09-25 Sumitomo Pharma Co Ltd Rokoteadjuvanttiformulaatio
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
TW202015725A (zh) * 2018-06-04 2020-05-01 美商亞博創新醫藥有限公司 Tlr7 肽結合物
TW202003475A (zh) 2018-06-04 2020-01-16 美商亞博創新醫藥有限公司 含酸性基團之嘧啶化合物
PH12021550175A1 (en) 2018-07-23 2022-07-11 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Composition containing influenza vaccine
MX2021012201A (es) 2019-04-05 2022-01-06 Sumitomo Pharma Co Ltd Adyuvante soluble en agua.
US20220241402A1 (en) 2019-06-18 2022-08-04 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
JP2023551798A (ja) * 2020-11-18 2023-12-13 ロンザ・ベンド・インコーポレーテッド 血管新生阻害剤を含む吸入可能な乾燥粉末製剤
CN117379535B (zh) * 2023-12-08 2024-03-15 中国人民解放军总医院第二医学中心 肝细胞生长因子在制备变应性鼻炎的药物中的应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2657206A (en) * 1951-07-30 1953-10-27 Burroughs Wellcome Co 2, 4-diamino-5-aryloxy-pyrimidines
GB1375162A (enExample) 1970-10-22 1974-11-27
GB1546937A (en) * 1976-07-29 1979-05-31 Beecham Group Ltd 2,4-diaminopyrimidine derivatives
US4505910A (en) * 1983-06-30 1985-03-19 American Home Products Corporation Amino-pyrimidine derivatives, compositions and use
GR82004B (enExample) * 1983-06-30 1984-12-12 American Home Prod
ZA848968B (en) * 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
IL78643A0 (en) * 1985-05-02 1986-08-31 Wellcome Found Purine derivatives,their preparation and pharmaceutical compositions containing them
DE3603577A1 (de) * 1986-02-06 1987-08-13 Joachim K Prof Dr Seydel Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit
GB8900382D0 (en) * 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
US5290933A (en) * 1989-04-26 1994-03-01 Smithkline & French Laboratories Limited Phenylpyrimidone derivatives
JPH08165292A (ja) 1993-10-07 1996-06-25 Techno Res Kk アデニン誘導体、その製造法及び用途
US6110923A (en) * 1994-06-22 2000-08-29 Biochem Pharma Inc. Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
PL319485A1 (en) * 1994-10-05 1997-08-04 Chiroscience Ltd Purinic and guanic compounds as pnp inhibitors
ATE283855T1 (de) * 1996-07-03 2004-12-15 Sumitomo Pharma Neue purinderivate
CA2311742C (en) * 1997-11-28 2009-06-16 Sumitomo Pharmaceuticals Co., Ltd. 6-amino-9-benzyl-8-hydroxypurine derivatives
TW572758B (en) * 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
EP1054871A2 (en) 1998-04-01 2000-11-29 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
DE69917469T2 (de) * 1998-08-27 2005-05-12 Sumitomo Pharmaceuticals Co., Ltd. Pyrimidin derivate
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
WO2001007027A2 (en) 1999-07-22 2001-02-01 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives for the treatment of viral diseases
US20020128264A1 (en) * 2000-07-07 2002-09-12 Taylor Eve M. Methods for treatment of conditions affected by activity of multidrug transporters
DE60228229D1 (de) * 2001-04-17 2008-09-25 Dainippon Sumitomo Pharma Co Neue adeninderivate
WO2004003198A1 (ja) * 2002-06-27 2004-01-08 Genox Research, Inc. アレルギー性疾患の検査方法、および治療のための薬剤
NZ539064A (en) 2002-09-27 2007-09-28 Dainippon Sumitomo Pharma Co Novel adenine compound and use thereof
WO2004081173A2 (en) * 2003-03-12 2004-09-23 Evogene Ltd. Nucleotide sequences regulating gene expression and constructs and methods utilizing same
EA200600069A1 (ru) * 2003-06-20 2006-08-25 Коли Фармасьютикал Гмбх Низкомолекулярные антагонисты toll-подобных рецепторов (tlr)
CN1809357B (zh) * 2003-06-20 2010-12-22 科勒制药有限公司 小分子Toll样受体(TLR)拮抗剂
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2005025583A2 (en) * 2003-09-05 2005-03-24 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
TWI392678B (zh) 2004-03-26 2013-04-11 Dainippon Sumitomo Pharma Co ９-取代-８-氧基腺嘌呤化合物
EP1728792A4 (en) * 2004-03-26 2010-12-15 Dainippon Sumitomo Pharma Co 8-OXOADENINE COMPOUND
KR100700676B1 (ko) 2005-06-24 2007-03-28 (주) 비엔씨바이오팜 6―（4―치환된―아닐리노）피리미딘 유도체, 그 제조방법및 이를 포함하는 항바이러스용 약학적 조성물
ZA200802411B (en) 2005-09-15 2009-09-30 Orchid Res Lab Ltd Novel pyrimidine carboxamides
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
WO2007034917A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物
EP1939198A4 (en) 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
JPWO2007034882A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
JPWO2007034817A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
US20090099216A1 (en) * 2005-09-22 2009-04-16 Astrazeneca Aktiebolag A Corporation Of Sweden Novel adenine compound
UY30444A1 (es) 2006-06-30 2008-01-31 Astrazeneca Ab Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
WO2008004948A1 (en) 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
CL2007002231A1 (es) 2006-08-02 2008-04-11 Basf Ag Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico.
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
WO2008083465A1 (en) 2007-01-08 2008-07-17 University Health Network Pyrimidine derivatives as anticancer agents
WO2008114008A1 (en) 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
EP2139894B1 (en) 2007-03-19 2011-10-26 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
EP2138497A4 (en) 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
JP5400763B2 (ja) 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
JPWO2009091031A1 (ja) 2008-01-17 2011-05-26 大日本住友製薬株式会社 アデニン化合物の製造方法
CN102143964A (zh) 2008-01-17 2011-08-03 大日本住友制药株式会社 制备腺嘌呤化合物的方法
WO2010033074A1 (en) 2008-09-18 2010-03-25 Astrazeneca Ab Use of a tlr7 agonist for the treatment of cancer
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
EP2507237A1 (en) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)

Also Published As

Publication number Publication date
UA99484C2 (ru) 2012-08-27
CN101925584A (zh) 2010-12-22
CN103342682A (zh) 2013-10-09
TW200927123A (en) 2009-07-01
DOP2010000153A (es) 2010-07-15
US20130045955A1 (en) 2013-02-21
EP2222648B1 (en) 2013-01-09
EP2222648A1 (en) 2010-09-01
CA2704214A1 (en) 2009-05-28
IL205513A0 (en) 2010-12-30
JP5638394B2 (ja) 2014-12-10
JP2011504497A (ja) 2011-02-10
KR20100095610A (ko) 2010-08-31
SA08290741B1 (ar) 2012-01-24
EA018121B1 (ru) 2013-05-30
KR101663326B1 (ko) 2016-10-06
PE20091236A1 (es) 2009-09-16
AU2008326863B2 (en) 2012-01-19
CR11451A (es) 2010-10-05
CL2008003480A1 (es) 2009-06-05
CY1113846T1 (el) 2016-07-27
RS52694B (sr) 2013-08-30
ES2401401T3 (es) 2013-04-19
ME01515B (me) 2014-04-20
NZ585313A (en) 2012-04-27
SI2222648T1 (sl) 2013-06-28
CO6270324A2 (es) 2011-04-20
CA2704214C (en) 2016-05-24
HRP20130174T1 (hr) 2013-03-31
EP2222648A4 (en) 2010-12-08
US20090209524A1 (en) 2009-08-20
WO2009067081A1 (en) 2009-05-28
CN101925584B (zh) 2013-04-17
ECSP10010294A (es) 2010-07-30
HK1147749A1 (en) 2011-08-19
AR069412A1 (es) 2010-01-20
EA201000830A1 (ru) 2011-02-28
US8268990B2 (en) 2012-09-18
PT2222648E (pt) 2013-03-07
BRPI0819788A2 (pt) 2015-05-05
ZA201003476B (en) 2013-10-30
TWI461198B (zh) 2014-11-21
AU2008326863A1 (en) 2009-05-28
HN2010001059A (es) 2012-08-24
DK2222648T3 (da) 2013-03-18
UY31481A1 (es) 2009-07-17
MX2010005435A (es) 2010-06-11
US8765939B2 (en) 2014-07-01

Similar Documents

Publication Publication Date Title
EP2222648A4 (en) PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIAN DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS
EP2709989B8 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
IL250858A0 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
WO2011056650A9 (en) Methods and compositions for treating and preventing viral infections
SG11201502622VA (en) PYRROLO[3,2-<i>D</i>]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
IL187135A0 (en) 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
ZA201001392B (en) 2,3-substituted azaindole derivatives for treating viral infections
ZA201001391B (en) Tetracyclic indole derivatives and their use for treating or preventing viral infections
IL200848A0 (en) Solid dispersions of imatinib and processes for producing the same
ZA201005737B (en) Methods of treating viral infections
IL209503A0 (en) Heterocyclic urea derivatives for the treatment of bacterial infections
GB2455585B (en) Capsicum seeds for the treatment of eczema and dermatitis
ZA200904068B (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
EP2164515A4 (en) PROCESS FOR TREATING ATOPIC ECZEMA
SI2766367T1 (sl) 4-amino-3-fenilamino-6-fenilpirazol(3,4-D)primidinski derivati za zdravljenje virusnih okužb, zlasti pikornavirusnih okužb
GB0608792D0 (en) Method for treatment and prophylaxis of viral influenza infections
HK1165996A (en) Compounds and methods for treating cancer and viral infections
HK1139603A (en) Method for the treatment of atopic eczema
HK1157264A (en) Devices for treatment of viral infections
HK1143813A (en) Tetracyclic indole derivatives and their use for treating or preventing viral infections
HK1170165A (en) Derivatives of n-hydroxybenzamide for treating hiv infections
HK1134521A (en) Dsrna compositions and methods for treating hpv infections
HK1154855A (en) Heterocyclic urea derivatives for the treatment of bacterial infections
SI2155758T1 (sl) Tetrahidrofuro(3,4-d)dioksolanske spojine za uporabo pri zdravljenju virusnih infekcij in raka
HK1143818A (en) 2,3-substituted azaindole derivatives for treating viral infections